Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Latest Information Update: 08 Nov 2021
At a glance
- Drugs BMS 936559 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 18 Apr 2017 Results published in the Journal of Infectious Diseases
- 25 Feb 2016 Pre-specified analysis (n=8) presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
- 28 Dec 2015 Status changed from suspended to completed as reported by ClinicalTrials.gov.